Surgery Partners (SGRY) Could Be 20% Undervalued Following Its Recent Bounce
Surgery Partners (SGRY) has been drawing attention after recent share performance, which includes a decline of about 5% over the past month and roughly 6% over the past 3 months.
Viewed against the past year, where the total shareholder return is down 34.3% and the 5 year total shareholder return is lower again, Surgery Partners’ recent 1 day share price gain of 1.84% and modest 7 day share price return of 0.84% suggest only tentative momentum as investors reassess both growth prospects and risk.
Scan how Surgery Partners compares with other healthcare operators under pressure by checking the hand picked list of solid balance sheet and fundamentals (23 results) that still show resilient financial footing despite recent share price weakness.
The recent bounce in Surgery Partners after a steep multi year decline raises a basic issue: Is this a small verdict on the underlying business or just another turn in sentiment before the next move on valuation?
Most Popular Narrative: 19.9% Undervalued
Surgery Partners closed at $14.38, while the most followed narrative pegs fair value at $17.95, creating a clear valuation gap that hinges on how margins and growth progress from here.
Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.
Want to see how this story holds together over time? The narrative links modest revenue growth, a profit turnaround, and a rich future earnings multiple into one tightly argued valuation case.
Result: Fair Value of $17.95 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, this narrative can crack if anesthesia costs continue to squeeze margins or if slower acquisitions leave Surgery Partners short of its EBITDA ambitions.
Find out about the key risks to this Surgery Partners narrative.
Next Steps
Curious whether the cautious tone around Surgery Partners really fits the full picture? Take a closer look at the optimism already reflected in the data with 4 key rewards.
Looking for more investment ideas beyond Surgery Partners?
Do not stop with one ticker. Broaden your watchlist with focused stock ideas that match your risk profile and income goals before the next move catches you off guard.
- Target potential mispricings by scanning a curated pool of quality stocks with 31 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that feature 6 dividend fortresses.
- Dial back risk while staying invested by filtering for 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com